Aladar Szalay Sells 6,025 Shares of Genelux Co. (NASDAQ:GNLX) Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 6,025 shares of the business’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $3.67, for a total value of $22,111.75. Following the transaction, the insider now owns 1,189,706 shares of the company’s stock, valued at approximately $4,366,221.02. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, May 1st, Aladar Szalay sold 33,061 shares of Genelux stock. The shares were sold at an average price of $3.30, for a total transaction of $109,101.30.
• On Monday, April 29th, Aladar Szalay sold 6,403 shares of Genelux stock. The stock was sold at an average price of $3.25, for a total value of $20,809.75.
• On Wednesday, April 24th, Aladar Szalay sold 8,064 shares of Genelux stock. The stock was sold at an average price of $3.50, for a total value of $28,224.00.
• On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total transaction of $50,588.43.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total transaction of $171,850.99.

Genelux Stock Performance

Shares of Genelux stock traded up $0.23 during midday trading on Thursday, hitting $4.02. The company had a trading volume of 101,378 shares, compared to its average volume of 124,666. Genelux Co. has a 12-month low of $3.06 and a 12-month high of $40.98. The company has a fifty day simple moving average of $5.04 and a 200 day simple moving average of $9.74.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings data on Friday, March 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Sell-side analysts expect that Genelux Co. will post -0.81 EPS for the current year.

Institutional Investors Weigh In On Genelux

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Genelux by 1,660.1% in the 3rd quarter. Vanguard Group Inc. now owns 980,993 shares of the company’s stock valued at $24,025,000 after purchasing an additional 925,258 shares during the period. D.A. Davidson & CO. acquired a new position in Genelux in the 3rd quarter worth about $237,000. Advisor Resource Council acquired a new stake in Genelux in the fourth quarter valued at approximately $233,000. Barclays PLC increased its position in shares of Genelux by 516.4% in the third quarter. Barclays PLC now owns 3,384 shares of the company’s stock valued at $83,000 after buying an additional 2,835 shares in the last quarter. Finally, Whittier Trust Co. purchased a new position in shares of Genelux during the 3rd quarter valued at approximately $175,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. HC Wainwright dropped their target price on Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Benchmark reissued a “speculative buy” rating and set a $30.00 price target on shares of Genelux in a research report on Wednesday, April 3rd.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.